Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2025)
Prothena Corp Public's (PRTA) quarterly Cash from Investing Activities came in at -$10000.0 in Q3 2025, down 11.11% year-on-year from -$11250.0 in Q3 2024, and up 88.37% quarter-over-quarter from -$86000.0 in Q2 2025.
Prothena Corp Public (PRTA) Cash from Investing Activities (2012 - 2025) Analysis & Trends
Prothena Corp Public's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at -$10000.0 for Q3 2025.
- On a quarterly basis, Cash from Investing Activities fell 11.11% year-over-year to -$10000.0 in Q3 2025; TTM through Mar 2026 was -$96000.0, a 59.49% increase from a year earlier, with the FY2025 full-year figure at -$138000.0, up 53.69% from the prior year.
- Cash from Investing Activities improved to -$10000.0 in Q3 2025 per PRTA's latest filing, from -$86000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$9000.0 in Q3 2024 and bottomed at -$1.5 million in Q4 2023.
- The 5-year median for Cash from Investing Activities is -$116500.0 (2022), against an average of -$236000.0.
- Across the five-year window, Cash from Investing Activities sank 901.32% in 2023 and jumped 97.96% in 2024, its largest moves.
- Year by year, Cash from Investing Activities stood at -$319000.0 in 2021, then jumped by 52.66% to -$151000.0 in 2022, then sank by 901.32% to -$1.5 million in 2023, then soared by 97.16% to -$43000.0 in 2024, then jumped by 76.74% to -$10000.0 in 2025.
- Per Business Quant, the three latest PRTA Cash from Investing Activities figures stand at -$10000.0 (Q3 2025), -$86000.0 (Q2 2025), and -$42000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Prothena Corp Public | 473.44 Mn | 143.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,000.00 |
| Sep 30, 2025 | -10,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Jun 30, 2025 | -86,000.00 |
| Mar 31, 2025 | -42,000.00 |
| Mar 31, 2025 | -42,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Dec 31, 2024 | -43,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Sep 30, 2024 | -9,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.51 Mn |
| Dec 31, 2023 | -1.51 Mn |
| Sep 30, 2023 | -442,000.00 |
| Sep 30, 2023 | -442,000.00 |
| Jun 30, 2023 | -771,000.00 |
| Jun 30, 2023 | -771,000.00 |